{
    "root": "cab8eef9-3094-4824-a5a6-3e11cd06853c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Valganciclovir",
    "value": "20250310",
    "ingredients": [
        {
            "name": "VALGANCICLOVIR HYDROCHLORIDE",
            "code": "4P3T9QF9NZ"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "valganciclovir tablets deoxynucleoside analogue cytomegalovirus ( cmv ) dna polymerase inhibitor indicated : adult patients ( 1.1 ) \u2022 treatment cmv retinitis patients acquired immunodeficiency syndrome ( aids ) . \u2022 prevention cmv disease kidney , heart , kidney-pancreas transplant patients high risk . pediatric patients ( 1.2 ) \u2022 prevention cmv disease kidney heart transplant patients high risk",
    "contraindications": "adult ( 2.2 ) treatment cmv retinitis induction : 900 mg ( two 450 mg tablets ) twice day 21 days maintenance : 900 mg ( two 450 mg tablets ) day prevention cmv disease heart kidney-pancreas transplant patients 900 mg ( two 450 mg tablets ) day within 10 days transplantation 100 days post-transplantation prevention cmv disease kidney transplant patients 900 mg ( two 450 mg tablets ) day within 10 days transplantation 200 days post-transplantation pediatric ( 2.3 ) prevention cmv disease kidney transplant patients 4 months 16 years age dose day within 10 days transplantation 200 days post-transplantation according algorithm ( note calculation creatinine clearance using modified schwartz formula children ) prevention cmv disease heart transplant patients 1 month 16 years age dose day within 10 days transplantation 100 days post-transplantation according algorithm ( note calculation creatinine clearance using modified schwartz formula children ) \u2022 valganciclovir tablets taken food . ( 2.1 , 12.3 ) \u2022 valganciclovir tablets broken crushed . ( 2.6 ) \u2022 adult patients valganciclovir tablets , valganciclovir oral solution . ( 2.1 ) \u2022 adults renal impairment : adjust dose based creatinine clearance . adult patients receiving hemodialysis dose recommendation given .",
    "warningsAndPrecautions": "valganciclovir tablets usp , 450 mg pink , oval , biconvex , film-coated tablets , debossed ' j ' one side '156 ' side . film-coated tablet contains 496.3 mg valganciclovir hydrochloride , usp equivalent 450 mg valganciclovir . valganciclovir tablets supplied : cartons 20 film-coated tablets ( 10 film-coated tablets blister pack x 2 ) , ndc 0904-6796-10 cartons 30 film-coated tablets ( 10 film-coated tablets blister pack x 3 ) , ndc 0904-6796-04 store 25 \u00b0c ; excursions permitted 15 \u00b0 30 \u00b0c ( 59 \u00b0and 86 \u00b0f ) . [ usp controlled room temperature . ]",
    "adverseReactions": "valganciclovir tablets contraindicated patients demonstrated clinically significant hypersensitivity reaction ( e.g . , anaphylaxis ) valganciclovir , ganciclovir , component formulation [ ( 6.1 ) ] .",
    "indications_original": "Valganciclovir tablets are a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) \u2022\u00a0Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). \u2022\u00a0Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients ( 1.2 ) \u2022\u00a0Prevention of CMV disease in kidney and heart transplant patients at high risk",
    "contraindications_original": "Adult Dosage (2.2) Treatment of CMV retinitis Induction: 900 mg (two 450 mg tablets) twice a day for 21 days Maintenance: 900 mg (two 450 mg tablets) once a day Prevention of CMV disease in heart or kidney-pancreas transplant patients 900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 100 days post-transplantation Prevention of CMV disease in kidney transplant patients 900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 200 days post-transplantation Pediatric Dosage (2.3) Prevention of CMV disease in kidney transplant patients 4 months to 16 years of age Dose once a day within 10 days of transplantation until 200 days post-transplantation according to dosage algorithm (note the calculation of creatinine clearance using a modified Schwartz formula in children) Prevention of CMV disease in heart transplant patients 1 month to 16 years of age Dose once a day within 10 days of transplantation until 100 days post-transplantation according to dosage algorithm (note the calculation of creatinine clearance using a modified Schwartz formula in children) \u2022\u00a0Valganciclovir tablets should be taken with food. ( 2.1 , 12.3 ) \u2022\u00a0Valganciclovir tablets should not be broken or crushed. ( 2.6 ) \u2022\u00a0Adult patients should use valganciclovir tablets, not valganciclovir for oral solution. ( 2.1 ) \u2022\u00a0Adults with renal impairment: Adjust dose based on creatinine clearance. For adult patients receiving hemodialysis a dose recommendation cannot be given.",
    "warningsAndPrecautions_original": "Valganciclovir tablets USP, 450 mg are pink, oval, biconvex, film-coated tablets, debossed with 'J' on one side and '156' on the other side. Each film-coated tablet contains 496.3 mg of valganciclovir hydrochloride, USP equivalent to 450 mg of valganciclovir. Valganciclovir tablets are supplied in:\n                  Cartons of 20 film-coated tablets (10 film-coated tablets each blister pack x 2), NDC 0904-6796-10 \n                  Cartons of 30 film-coated tablets (10 film-coated tablets each blister pack x 3), NDC 0904-6796-04\n                  Store at 25 \u00b0C; excursions permitted between 15 \u00b0 and 30 \u00b0C (59 \u00b0and 86 \u00b0F). [See USP Controlled Room Temperature.]",
    "adverseReactions_original": "Valganciclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation     [see Adverse Reactions (       6.1)]."
}